No Prescription |
 |
 | ||
|
Ultraproct Generic fluocortolone pivalate |
|
| ||
No Prescription » Prescription Drugs 16 » Ultraproct Generic fluocortolone pivalate IndicationsHaemorrhoids superficial anal fissures proctitis.Dosage and AdministrationThe anal region should be cleaned thoroughly before using ULTRAPROCT« which is best applied after defaecation. There is usually a rapid improvement but this should not mislead one into stopping treatment too soon. To avoid relapses ULTRAPROCT« should be continued for at least one week though less frequently (ointment once a day or one suppository every other day) even when the symptoms have completely disappeared. However duration of treatment should as far as possible not exceed 4 weeks.OintmentGenerally ULTRAPROCT« ointment is applied twice daily. On the first day for faster symptomatic relief it can be applied up to four times a day. A little ointment (about the size of a pea) is smeared around the anus and in the anal ring with a finger using the fingertip to overcome the resistance of the sphincter. Before applying within the rectum the enclosed nozzle should be screwed on to the tube. However for very inflamed and hence painful lesions it is advisable initially to apply the ointment internally with the finger. Protruding lumps should be smeared thickly and pressed carefully back with the finger. Buy Ultraproct Generic fluocortolone pivalate and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About Ultraproct Generic fluocortolone pivalate: Product Type: Prescription Drugs 16 Ultraproct ( Generic fluocortolone pivalate fluocortolone hexanoate and cinchocaine hydrochloride ) Ultraproct (Generic fluocortolone pivalate fluocortolone hexanoate and cinchocaine hydrochloride) Generic fluocortolone pivalate fluocortolone hexanoate and cinchocaine hydrochloride 0.92/0.95/5mg Generic fluocortolone pivalate fluocortolone hexanoate and cinchocaine hydrochloride Ultraproct
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
